KEAP1 and cancer: Mutations hyperactivating the NRF2 pathway, often through NRF2 gain‐of‐function or KEAP1 loss‐of‐function, are prevalent in cancers like lung and liver.[62] Constitutive NRF2 activation enhances antioxidant defenses by increasing GSH, NADPH, and other reducing equivalents, conferring resistance to oxidative damage and therapy‐induced ROS.[53b] Although beneficial for cellular growth, this highly reducing environment introduces a vulnerability, as the excessive accumulation of reductants may exceed cellular tolerance thresholds, thereby triggering reductive stress.